|  |  |
| --- | --- |
|  | **NHS Prescription Services**Bridge House152 Pilgrim StreetNewcastle upon TyneNE1 6SN0845 850 0001nhsbsa.prescriptionservices@nhs.net[www.nhsbsa.nhs.uk](http://www.nhsbsa.nhs.uk)  28 November 2022 |
|  |

VERSION 11.3.0

Dear dm+d User,

**Part VIIIB Pack Size and Price Correction for Fexofenadine 180mg/5ml Oral Suspension**

The November 2022 Drug Tariff correctly indicates that a 100ml pack is priced at £245.96.

Unfortunately, in error, a 200ml pack was added to dm+d at the price of £245.96.

This has been corrected and a 100ml pack has now been added to dm+d.

There will be no impact on reimbursement. Reimbursement will be in line with the November 2022 Drug Tariff.

The 200ml pack has been invalidated too.

**dm+d stakeholder engagements to understand impacts of VMP SNOMED ID code changes**

The dm+d is undergoing some enhancements in the near future, one of which are a number (circa 2300) of VMP SNOMED ID code changes.

In order for us to implement these changes smoothly, we are engaging with users of dm+d data so that we can understand how the code changes will be handled and the volume of code changes that can be processed. NHS Digital colleagues have already started these engagements. If you think that this work will impact you and you have not yet been contacted, please email kerry.frenz2@nhs.net and paul.wright39@nhs.net. A roll out plan of the code changes will be communicated once stakeholders have been engaged.

**Update Re: Interesting Excipients authoring in dm+d to come to an end**

Following previous communications ‘Interesting’ excipient data will not be visible in the dm+d files from Monday 24th October 2022 onwards.

If you have any questions, please contact nhsbsa.dmdenquiries@nhs.net

A test file has been added to the Test Release Area of [TRUD](https://isd.digital.nhs.uk/trud/users/guest/filters/0/categories/6) for recipients of dm+d data to use.

**DHSC require these concepts to be made available and visible (similar to licensed medicines) in prescribing and dispensing systems for the time being.**

|  |
| --- |
| **Specials/Imports added at request of DHSC to mitigate shortages in the supply chain** |
| **AMP Name** | **AMP SNOMED Code** | **Import/Special** | **dm+d extract date** |
| Desmopressin 150micrograms/dose nasal spray | 38955011000001100 | Imported  | 14/09/2020 |
| Desmopressin 150micrograms/dose nasal spray | 38996011000001101 | Special Order | 21/09/2020 |
| Cloral betaine 707mg tablets | 39069011000001104 | Imported | 12/10/2020 |
| Gynokadin 0.06% gel | 40714711000001102 | Imported (Germany) |  13/06/2022 |
| Oestraclin 0.06% gel | 40714911000001100 | Imported (Spain) |  13/06/2022 |
| Sandrena 1mg gel sachets | 40715411000001109 | Imported (Italy) |  13/06/2022 |
| Lenzetto 1.53mg/dose transdermal spray | 40715811000001106 | Imported (Poland) |  13/06/2022 |
| Ovestin 1mg cream | 40716111000001105 | Imported (Germany) |  13/06/2022 |
| Promethazine hydrochloride 25mg tablets | 40822911000001101 | Imported |  18/07/2022 |
| Temazepam 10mg tablets | 41082311000001100 | Imported |  03/10/2022 |

**Invalidations**

None

**Advance Notice of Invalidations**

The following concepts will be invalidated mid-Dec. The products were added erroneously.

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**N/A | **VMP**N/A |
| **VMP SNOMED ID**N/A | **VMP SNOMED ID**N/A |
| **VMPP**N/A | **VMPP**N/A |
| **VMPP SNOMED ID**N/A | **VMPP SNOMED ID**N/A |
| **AMP**Isosorbide mononitrate 20mg tablets (Milpharm Ltd) | **AMP**N/A |
| **AMP SNOMED ID**35162811000001101 | **AMP SNOMED ID**N/A |
| **AMPP**56 tablets | **AMPP**N/A |
| **AMPP SNOMED ID**35162911000001106 | **AMPP SNOMED ID**N/A |

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**N/A | **VMP**N/A |
| **VMP SNOMED ID**N/A | **VMP SNOMED ID**N/A |
| **VMPP**N/A | **VMPP**N/A |
| **VMPP SNOMED ID**N/A | **VMPP SNOMED ID**N/A |
| **AMP**Isosorbide mononitrate 40mg tablets (Milpharm Ltd) | **AMP**N/A |
| **AMP SNOMED ID**35163011000001103 | **AMP SNOMED ID**N/A |
| **AMPP**56 tablets | **AMPP**N/A |
| **AMPP SNOMED ID**35163111000001102 | **AMPP SNOMED ID**N/A |

The following concepts will be invalidated mid-Jan. The company has informed us that they have not released the product as intended.

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**N/A | **VMP**N/A |
| **VMP SNOMED ID**N/A | **VMP SNOMED ID**N/A |
| **VMPP**N/A | **VMPP**N/A |
| **VMPP SNOMED ID**N/A | **VMPP SNOMED ID**N/A |
| **AMP**Toldelo XL 2mg capsules (Morningside Healthcare Ltd) | **AMP**N/A |
| **AMP SNOMED ID**40853811000001104 | **AMP SNOMED ID**N/A |
| **AMPP**28 | **AMPP**N/A |
| **AMPP SNOMED ID**40853911000001109 | **AMPP SNOMED ID**N/A |

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP** | **VMP** |
| N/A | N/A |
| **VMP SNOMED ID** | **VMP SNOMED ID** |
| N/A | N/A |
| **VMPP** | **VMPP** |
| N/A | N/A |
| **VMPP SNOMED ID** | **VMPP SNOMED ID** |
| N/A | N/A |
| **AMP** | **AMP** |
| Toldelo XL 4mg capsules (Morningside Healthcare Ltd) | N/A |
| **AMP SNOMED ID** | **AMP SNOMED ID** |
| 40854011000001100 | N/A |
| **AMPP** | **AMPP** |
| 28 | N/A |
| **AMPP SNOMED ID** | **AMPP SNOMED ID** |
| 40854111000001100 | N/A |

The following concepts will be invalidated mid-Jan. The products have never been marketed in the UK by the company below.

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**N/A | **VMP**N/A |
| **VMP SNOMED ID**N/A | **VMP SNOMED ID**N/A |
| **VMPP**N/A | **VMPP**N/A |
| **VMPP SNOMED ID**N/A | **VMPP SNOMED ID**N/A |
| **AMP**Azocan 150mg capsules (FDC International Ltd) | **AMP**N/A |
| **AMP SNOMED ID**37147411000001108 | **AMP SNOMED ID**N/A |
| **AMPP**1 capsule | **AMPP**N/A |
| **AMPP SNOMED ID**37147511000001107 | **AMPP SNOMED ID**N/A |

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**N/A | **VMP**N/A |
| **VMP SNOMED ID**N/A | **VMP SNOMED ID**N/A |
| **VMPP**N/A | **VMPP**N/A |
| **VMPP SNOMED ID**N/A | **VMPP SNOMED ID**N/A |
| **AMP**Azocan 200mg capsules (FDC International Ltd) | **AMP**N/A |
| **AMP SNOMED ID**37147811000001105 | **AMP SNOMED ID**N/A |
| **AMPP**7 capsules | **AMPP**N/A |
| **AMPP SNOMED ID**37147911000001100 | **AMPP SNOMED ID**N/A |

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**N/A | **VMP**N/A |
| **VMP SNOMED ID**N/A | **VMP SNOMED ID**N/A |
| **VMPP**N/A | **VMPP**N/A |
| **VMPP SNOMED ID**N/A | **VMPP SNOMED ID**N/A |
| **AMP**Azocan 50mg capsules (FDC International Ltd) | **AMP**N/A |
| **AMP SNOMED ID**37148211000001108 | **AMP SNOMED ID**N/A |
| **AMPP**7 capsules | **AMPP**N/A |
| **AMPP SNOMED ID**37148311000001100 | **AMPP SNOMED ID**N/A |

dm+d Authoring Team